Chimeric Therapeutics Ltd has released a press release.
Chimeric Therapeutics: Half Year Report and Appendix 4D 31 December 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Story so far
Earlier from Chimeric Therapeutics
- Portfolio streamlined - return of CHM CLTX to City of Hope
- Funding and EGM update
- Quarterly Activities/Appendix 4C Cash Flow Report
- $8.4 M funding to drive CHM CDH17 and resignation of CMO
- Trading Halt
Later from Chimeric Therapeutics
- Chimeric receives $1.8 M advance on FY26 R&D tax incentive
- Consolidation/Split - CHM
- Minaris Delivers 100% Manufacturing and Release Success for Chimeric Therapeutics' CDH17 Autologous CAR‑T Program
- CHM announces positive Phase 1/2 data at ASCO
- Appointment of Financial Adviser for Strategic Review
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics